Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy in HIV-Infected Transgender Women
NCT03348163Phase 4Terminated
- Sponsor
- UTHealth Houston
- Start
- Jun 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by UTHealth Houston. Started Jun 2018; status: terminated.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03348163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03348163.